Skip to main content

Table 1 Baseline characteristic of the participants included in the analysis according to AIP quartiles

From: Association between the atherogenic index of plasma and major adverse cardiovascular events among non-diabetic hypertensive older adults

Variable AIP P value
Q1 Q2 Q3 Q4
N 2331 2329 2330 2333  
AIP, mean (SD) −0.39 (0.12) − 0.13 (0.05) 0.05 (0.06) 0.35 (0.17) < 0.001
Female, n (%) 1056 (45.30%) 891 (38.26%) 760 (32.62%) 600 (25.72%) < 0.001
Treatment
 Intensive, n (%) 1168 (50.11%) 1173 (50.36%) 1171 (50.26%) 1150 (49.29%) 0.882
BMI (Kg/m2), median (Q1-Q3) 27.02 (24.05–30.87) 28.59 (25.69–32.40) 29.63 (26.69–33.49) 30.42 (27.52–34.14) < 0.001
Age, y
 Overall 70.01 (9.53) 68.44 (9.41) 67.66 (9.19) 65.51 (8.98) < 0.001
  ≥ 75y, n (%) 871 (37.37%) 700 (30.06%) 615 (26.39%) 455 (19.50%) < 0.001
Race, n (%)      < 0.001
 Non-Hispanic White 1207 (51.78%) 1303 (55.95%) 1382 (59.31%) 1494 (64.04%)  
 Non-Hispanic Black 919 (39.43%) 790 (33.92%) 622 (26.70%) 454 (19.46%)  
 Hispanic 160 (6.86%) 201 (8.63%) 280 (12.02%) 337 (14.44%)  
 Other 45 (1.93%) 35 (1.50%) 46 (1.97%) 48 (2.06%)  
Baseline BP, mm Hg
 Systolic (mm Hg) 140.94 (16.03) 139.82 (15.52) 139.20 (15.58) 138.71 (15.09) < 0.001
 Diastolic (mm Hg) 77.15 (12.42) 78.00 (11.83) 77.85 (11.45) 79.51 (11.93) < 0.001
Distribution of systolic BP, n (%)    < 0.001
  ≤ 132 mmHg 712 (30.54%) 792 (34.01%) 798 (34.25%) 822 (35.23%)  
  > 132 to < 145 mmHg 738 (31.66%) 738 (31.69%) 771 (33.09%) 779 (33.39%)  
  ≥ 145 mmHg 881 (37.79%) 799 (34.31%) 761 (32.66%) 732 (31.38%)  
Baseline heart rate, bpm 65.39 (11.33) 65.79 (11.44) 66.11 (11.72) 67.61 (11.82) < 0.001
Serum creatinine, mg/dL 1.04 (0.32) 1.07 (0.32) 1.07 (0.34) 1.12 (0.37) < 0.001
Urine Albumin/Creatinine ratio, mg/g Cr, median (Q1-Q3) 9.84 (5.86–20.75) 9.09 (5.49–19.97) 9.33 (5.62–22.82) 9.71 (5.57–23.00) 0.047
Estimated GFR, mL.min − 1 1.73 m − 2, median (Q1-Q3) 72.32 (59.75–86.22) 70.92 (57.90–83.91) 71.84 (58.38–84.95) 70.17 (56.49–83.44) < 0.001
Fasting total cholesterol, mg/dL, median (Q1-Q3) 187.00 (162.00–214.00) 183.00 (158.00–209.00) 185.00 (158.00–212.00) 193.00 (168.00–223.00) < 0.001
Fasting total TGs, mg/dL, median (Q1-Q3) 63.00 (54.00–74.00) 90.00 (80.00–104.00) 123.00 (109.00–138.00) 194.00 (162.00–242.00) < 0.001
Fasting HDL-C, mg/dL, median (Q1-Q3) 66.00 (57.00–76.00) 53.00 (48.00–60.00) 47.00 (42.00–53.00) 40.00 (36.00–46.00) < 0.001
Fasting glucose, mg/dL, median (Q1-Q3) 95.00 (89.00–101.00) 96.00 (90.00–104.00) 98.00 (91.00–106.00) 100.00 (93.00–109.00) < 0.001
Statin use, n (%) 916 (39.65%) 1042 (44.99%) 1081 (46.76%) 1007 (43.33%) < 0.001
Aspirin use, n (%) 1182 (50.86%) 1197 (51.42%) 1224 (52.65%) 1144 (49.16%) 0.120
TG-lowering drug, n (%) 533 (22.88%) 576 (24.73%) 653 (28.03%) 619 (26.53%) < 0.001
Smoking status, n (%)      0.006
 Never smoked 1088 (46.68%) 1031 (44.27%) 1024 (43.95%) 968 (41.49%)  
 Former smoker 964 (41.36%) 994 (42.68%) 1006 (43.18%) 999 (42.82%)  
 Current smoker 276 (11.84%) 302 (12.97%) 296 (12.70%) 364 (15.60%)  
Framingham 10-y CVD risk score, %, median (Q1-Q3) 14.71 (10.27–21.61) 16.80 (11.33–24.24) 18.49 (12.68–26.77) 21.39 (15.08–30.26) < 0.001
Previous CVD, n (%) 420 (18.02%) 466 (20.01%) 502 (21.55%) 481 (20.62%) 0.021
Previous CKD, n (%) 596 (25.57%) 673 (28.90%) 641 (27.51%) 735 (31.50%) < 0.001
Primary outcome 103 (4.42%) 137 (5.88%) 150 (6.44%) 171 (7.33%) < 0.001